Cite

HARVARD Citation

    Leifer, E. et al. (2019). Discussion of "A Hybrid Phase I‐II/III Clinical Trial Design Allowing Dose Re‐Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall. Biometrics. 75 (2), pp. 382-384. [Online]. 
  
Back to record